Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14004242 | 0.96 | ALDH1A1 (0.56) | ALDH1A1RECQLNR1I2POLBGAA | |
| SCHEMBL4687161 | 0.92 | ALOX15 (0.52) | ALDH1A1RECQLNR1I2POLBGAA | |
| SCHEMBL21876548 | 0.89 | APP (0.59) | ALDH1A1RECQLPOLBCYP3A4SMN1; SMN2 | |
| SCHEMBL20128986 | 0.89 | APP (0.59) | ALDH1A1RECQLPOLBCYP3A4SMN1; SMN2 | |
| SCHEMBL20294645 | 0.89 | APP (0.59) | ALDH1A1RECQLPOLBCYP3A4SMN1; SMN2 | |
| SCHEMBL15786150 | 0.89 | APP (0.59) | ALDH1A1RECQLPOLBCYP3A4SMN1; SMN2 | |
| SCHEMBL14211670 | 0.89 | APP (0.59) | ALDH1A1RECQLPOLBCYP3A4SMN1; SMN2 | |
| SCHEMBL577534 | 0.88 | LSS (0.53) | ALDH1A1RECQLPOLBKDM4EDRD4 | |
| SCHEMBL28106819 | 0.87 | ALDH1A1 (0.75) | ALDH1A1RECQLNR1I2GAACYP3A4 | |
| SCHEMBL48239 | 0.87 | ALDH1A1 (0.75) | ALDH1A1RECQLNR1I2GAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292417-A | Process for producing carboxylic acid | 赣南医学院 | 2021-08-24 | — | — | CN | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| WO-2025242566-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4653430-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-12325708-B2 | Adenosine 2 receptor antagonists | NEKTAR THERAPEUTICS (US) | 2025-06-10 | — | — | US | disclosed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| EP-4501912-A1 | NOVEL HETEROCYCLIC COMPOUND | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| EP-0403185-A2 | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0399635-A2 | Alkaline phenolic resole resin binders | BORDEN, INC. (US) | 1990-11-28 | — | — | EP | disclosed |
| US-4971132-A | Production of foundry molds and cores, placing a resole resin and refractory binder in a mold, gassing with a volatile ester | ACME RESIN CORPORATION (US) | 1990-11-20 | — | — | US | disclosed |
| EP-0389082-A2 | Alkaline benzylic ether phenolic resin binders | BORDEN, INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4946759-A | CLEAVAGE PRODUCT UNDER THE ACTION OF ACTINIC RADIATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-08-07 | — | — | US | disclosed |
| US-4929648-A | FOUNDRIES, MOLDINGS | ACME RESIN CORPORATION (US) | 1990-05-29 | — | — | US | disclosed |
| EP-0315748-A2 | Positive-working radiation-sensitive composistion and radiation-sensitive recording material produced therefrom | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-17 | — | — | EP | disclosed |
| US-4359424-A | Substituted phenoxyethoxytetrahydropyran | ZOECON CORPORATION (US) | 1982-11-16 | — | — | US | disclosed |
| US-4304924-A | Cyclopropylmethyl benzoates | ZOECON CORPORATION (US) | 1981-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | ALDH1A1 4449/4885RECQL 4032/4885NR1I2 2042/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | ALDH1A1 996/4885RECQL 1404/4885NR1I2 247/4885 |
| US-12325708-B2 | Adenosine 2 receptor antagonists | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 1202/4885RECQL 633/4885NR1I2 2240/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | ALDH1A1 4090/4885RECQL 3088/4885NR1I2 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.